RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Investor Event
RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), is pleased to announce an investor event on Wednesday 3rd November at 2.00pm.
Bill Brown, Chairman and Dr Caroline Stretton, Group MD will be joined by other key members of the management team. The event will be an opportunity for investors to hear directly from the company about the Vascular graft range, and discuss learnings from the October annual meeting of the European Association of Cardiothoracic Surgeons (EACTS) and latest 'in vivo' testing developments ahead of their 510k submission. Investors will also be able to get a closer look at the new site that will enable expansion of their manufacturing capacity and further dedicated R&D labs.
This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.
To register for the event, please click here
For more information please contact:
Equity Development
| Hannah Crowe
|
| 020 7065 2692 |
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
